We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Anti-angiogenic therapy in glioblastoma multiforme.
- Authors
Kozakiewicz, Paulina; Kordzińska-Cisek, Izabela; Król-Woch, Katarzyna; Stachyra, Paulina
- Abstract
Glioblastoma multiforme is the most common brain malignan-cy in adults. It is also highly aggressive and characterized by very poor prognosis. Surgical resection of the tumor remains the basic treatment that significantly improves survival. Moreover, adjuvant chemoradiotherapy is the standard-of-care. Glioblastoma multiforme has a very complex genetic profile; various genetic abnormalities have been discovered in cells of this type of tumor. Despite growing interest in targeted therapies in oncology, no breakthrough offering successful treatment of glioblastoma multiforme has occurred. Owing to the tumor's rich vasculature, antiangiogentic the-rapies seem promising. An association between carcinogene-sis and tumor vasculature was observed in 1970s. At present, the only FDA-approved drug targeting antiogenesis-stimula-ting factor is bevacizumab. In recent years, more and more new antiangiogenic therapies have been investigated in both monotherapy and combined treatment of glioblastoma mul-tiforme with different success rates. This article presents an overview of the most explored therapies.
- Subjects
GLIOBLASTOMA multiforme; CELL tumors; GENETIC disorders; CHEMORADIOTHERAPY; ONCOLOGY
- Publication
Onkologia i Radioterapia, 2018, Vol 44, Issue 2, p17
- ISSN
1896-8961
- Publication type
Article